LGALS3 and melanoma: The introduction and clinical application of Gal-3 inhibitors/antagonists strongly suggests that the accumulation of experimental and clinical evidence may open entirely new avenues for the treatment of skin inflammation and neoplastic diseases (psoriasis, atopic dermatitis, and melanoma).